Targeting Molecular Subsets in Metastatic Colorectal Cancer (dMMR, - - PowerPoint PPT Presentation
Targeting Molecular Subsets in Metastatic Colorectal Cancer (dMMR, HER2, or BRAF V600E): Is it Time for Frontline Targeted Therapy? Benjamin A. Weinberg, M.D. Assistant Professor of Medicine Lombardi Comprehensive Cancer Center Georgetown
Weinberg BA et al. Clin Adv Hematol Oncol 2016. de Gramont A et al. J Clin Oncol 2000. Hurwitz H et al. N Engl J Med 2004. Douillard JY et al. J Clin Oncol 2010. Souglakos J et al. Br J Cancer 2006. Van Cutsem E et al. J Clin Oncol 2011. Falcone A et al. J Clin Oncol 2007. Cremolini C et al. Lancet Oncol 2015.
Salem et al. Oncotarget 2017.
Le et al. N Engl J Med 2015.
Best Reduction in Target Lesion: All Patients
Presented By Michael Overman at 2018 Gastrointestinal Cancers Symposium
Best Reduction in Target Lesions
Presented By Thierry Andre at 2018 Gastrointestinal Cancers Symposium
Progression-Free and Overall Survival
Presented By Thierry Andre at 2018 Gastrointestinal Cancers Symposium
Safety Summary
Presented By Thierry Andre at 2018 Gastrointestinal Cancers Symposium
Slide 27
Presented By Neil Segal at 2018 ASCO Annual Meeting
Sartore-Bianchi et al. Lancet Oncol 2016.
Sartore-Bianchi et al. Lancet Oncol 2016. Siravegna et al. Clin Cancer Res 2019.
ORR 30%
Meric-Bernstam et al. Lancet Oncol 2019.
ORR 32%
Meric-Bernstam et al. Lancet Oncol 2019.
Raghav et al. ASCO AM 2018. Strickler et al. ASCO AM 2017.
Cremolini et al. Lancet Oncol 2015.
Introduction
Presented By Scott Kopetz at 2017 ASCO Annual Meeting
Study Design
Presented By Scott Kopetz at 2017 ASCO Annual Meeting
Primary Endpoint: Progression-free survival
Presented By Scott Kopetz at 2017 ASCO Annual Meeting
Secondary Endpoint: Overall Survival
Presented By Scott Kopetz at 2017 ASCO Annual Meeting
Kopetz et al. ESMO GI 2019.
Kopetz et al. NEJM 2019.
ORR 26% ORR 20% ORR 2%
Kopetz et al. NEJM 2019.